

Monday, 06 June 2022



IMVANEX suspension for injection

Smallpox vaccine (Live Modified Vaccinia Virus Ankara or MVA-BN)

Read all of this leaflet carefully before you receive this vaccine because it contains important information for you. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or nurse.

If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet.

What is in this leaflet

1. What IMVANEX is and what it is used for
2. Considerations for the use of IMVANEX for post exposure in children
3. What you need to know before you receive IMVANEX
4. How IMVANEX is given
5. Possible side effects

What IMVANEX is and what it is used for

MVA-BN (Imvanex) is a modified vaccinia Ankara vaccine, manufactured by Bavarian Nordic. It was initially developed to use for the prevention of smallpox. When a person is given the vaccine, the immune system (the body's natural defence system) will produce its own protection in the form of antibodies against the smallpox virus. IMVANEX does not contain smallpox virus and cannot spread or cause smallpox.

As monkeypox is caused by a virus similar to the one that causes smallpox, vaccines designed for smallpox are considered effective in preventing or reducing the severity of the monkeypox. Whilst this vaccine is not currently licensed for specific use against monkeypox in Europe, in September 2019, the vaccine received approval for use in the prevention of monkeypox from the US Food and Drug Administration. As this medicine (Imvanex) has been authorised by the European Medicines Agency for use as pre- and post-exposure prophylaxis for smallpox, the vaccine has been manufactured to a high standard and has undergone independent batch testing before release. The UK Health Security Agency (UKHSA) and the Joint Committee on Vaccination and Immunisation (JCVI) recommends its use in response to cases of monkeypox.

This leaflet describes the Imvanex vaccine, which the UK Health Security Agency (UKHSA) and the Joint Committee on Vaccination and Immunisation (JCVI) now recommends in response to cases of monkeypox.

Details

Format

A4 5 pages

Target group

Those at risk of monkeypox, Health Professionals

Downloads

Attachment

Size

[IMVANEX vaccination leaflet FINAL 0.pdf](#) 230.4 KB

Tags

- [immunisation vaccine vaccines](#)
- [monkeypox](#)
- [smallpox](#)

[Print](#)